Haemonetics Appoints Leadership to Boost Innovation and Operational Excellence in Healthcare
- Haemonetics appoints Frank Chan as Executive VP and COO to enhance innovation and operational excellence.
- Roy Galvin promoted to Executive VP and Chief Commercial Officer, focusing on Global Hospital and plasma initiatives.
- Leadership changes underscore Haemonetics' commitment to improving patient outcomes and navigating healthcare industry complexities.
Haemonetics Strengthens Leadership to Drive Innovation and Operational Excellence
Haemonetics Corporation, a leader in medical technology, announces pivotal changes to its Executive Leadership team to bolster its commitment to innovation and operational excellence. Effective April 7, 2025, Frank Chan, Ph.D., will join as Executive Vice President and Chief Operating Officer. In this role, Chan will oversee crucial areas such as research and development, regulatory affairs, and global manufacturing and supply chain operations. With over 25 years of experience in the medical device and healthcare technology sectors, Chan's previous leadership as President of Acute Care & Monitoring at Medtronic plc equips him with a robust background in delivering innovative healthcare solutions and expanding patient access on a global scale.
The appointment of Chan aligns with Haemonetics' strategic vision to enhance its product offerings and operational capabilities. Chris Simon, President and CEO of Haemonetics, underscores the importance of this leadership transition, highlighting Chan's proven track record in leading transformative initiatives within the industry. This move signals Haemonetics' intent to further solidify its position in the healthcare market, particularly in blood and plasma component collection, surgical suites, and hospital transfusion services. Chan's expertise is expected to play a vital role in fostering innovation and ensuring that Haemonetics continues to meet the evolving needs of healthcare providers and patients.
In conjunction with Chan's appointment, Roy Galvin, who joined Haemonetics in 2022 as President of Global Plasma and Blood Center, is elevated to Executive Vice President and Chief Commercial Officer. Galvin will assume immediate responsibility for the Global Hospital business along with the company’s plasma and blood center initiatives. His extensive experience and familiarity with scaling healthcare technology businesses position him as an asset in driving Haemonetics' growth strategy. Together, Chan and Galvin's contributions are poised to enhance Haemonetics' operational framework, enabling the company to focus on delivering high-quality medical solutions while improving patient outcomes and reducing healthcare costs.
In addition to these leadership changes, Haemonetics reaffirms its dedication to innovation in the medical technology landscape. The company aims to build a robust foundation for sustained success, setting the stage for the next phase of growth. With a renewed focus on critical markets, Haemonetics is well-positioned to navigate the complexities of the healthcare industry and respond to increasing demands for efficient and effective medical solutions. These strategic appointments reflect Haemonetics' commitment to excellence and innovation as it strives to enhance patient care globally.